Biomarker-Driven Therapeutic Management of Alzheimer's Disease: Establishing the Foundations

Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Amyloid measures become abnormal early in the Alzheimer's disease process and have only weak c...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical pharmacology and therapeutics Vol. 95; no. 1; pp. 67 - 77
Main Authors:	Cummings, J, Zhong, K
Format:	Journal Article
Language:	English
Published:	Basingstoke Blackwell Publishing Ltd 01-01-2014 Nature Publishing Group
Subjects:	Adult and adolescent clinical studies Alzheimer Disease - diagnosis Alzheimer Disease - metabolism Alzheimer Disease - therapy Amyloid beta-Peptides - metabolism Animals Biological and medical sciences Biomarkers - metabolism Brain - metabolism Brain - pathology Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disease Management Humans Medical sciences Neurology Organic mental disorders. Neuropsychology Pharmacology. Drug treatments Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Human Nervous system diseases Clinical management Treatment Alzheimer disease Central nervous system disease Biological marker Degenerative disease Management Cerebral disorder
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Amyloid measures become abnormal early in the Alzheimer's disease process and have only weak correlations with disease progression and cognitive decline; cerebrospinal fluid tau, brain atrophy, and reduced cortical metabolism correlate with cognitive measures and disease progression. Combinations of biomarkers have higher correlations and are better predictors of future decline than single biomarkers. Current biomarkers do not account for all of the variance in Alzheimer's disease; a more complete repertoire of biomarkers that more comprehensively assay the disease process is needed. Clinical Pharmacology & Therapeutics (2013); 95 1, 67–77 advance online publication 20 November 2013. doi:10.1038/clpt.2013.205
Bibliography:	ark:/67375/WNG-CS993K1H-G Supplementary Table S1Supplementary Table S2 istex:D9D0A0B8CD7AEF78D1890B14A66713F8052EA063 ArticleID:CPTCLPT2013205 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0009-9236 1532-6535
DOI:	10.1038/clpt.2013.205